Jiangsu Nanfang Medical(SH:603880) Xin Hua Wang·2025-08-12 05:49Core Viewpoint - The number of listed companies under investigation for violations has increased significantly, indicating a strict regulatory environment in China aimed at ensuring compliance and protecting investors [1][3]. Group 1: Regulatory Actions - A total of 67 listed companies and related parties have been investigated by regulatory authorities this year, with 20 companies being investigated in July alone [1]. - The investigations primarily focus on violations related to information disclosure, with some individuals facing charges for insider trading and bribery [1][2]. - The regulatory environment reflects a zero-tolerance approach towards illegal activities, as emphasized by experts [1][3]. Group 2: Company-Specific Cases - ST Nanwei was investigated for information disclosure violations, linked to the misuse of funds by its controlling shareholder, which had previously been flagged in audit reports [2]. - Historical data shows that ST Nanwei had significant fund misuse issues from 2020 to 2022, with amounts of 92 million, 135 million, and 132 million respectively [2]. - Another company faced investigation due to a board member's involvement in short-term trading, highlighting the risks associated with insider trading practices [2]. Group 3: Industry Trends - The number of listed companies investigated for violations has risen from 70 in 2021 to 91 in 2022, marking a significant increase in regulatory scrutiny [3]. - The shift towards a comprehensive registration system has intensified the need for compliance among listed companies, making adherence to regulations more critical than ever [3]. - Experts suggest that companies must enhance their governance structures and compliance awareness to avoid legal pitfalls and protect investor interests [3].